AltaThera Pharmaceuticals is focused on precision medicine, aiming to enhance patient care and reduce healthcare costs through innovative scientific approaches. The company is particularly dedicated to individualizing cardiovascular drug treatments for diverse patient populations, addressing the growing global issue of arrhythmias, such as Atrial Fibrillation (AFib). Their flagship product, Sotalol IV, represents a significant advancement in treatment delivery by converting a traditionally inpatient procedure into an outpatient one, thereby shortening hospital stays and alleviating burdens on both patients and healthcare providers.

The company employs model-informed drug development techniques that leverage human clinical data to create biological and statistical models. This approach not only identifies new uses for existing drugs but also enhances drug safety by detecting potential adverse events that may not surface during standard clinical trials. Additionally, AltaThera's methodologies are tailored to accommodate the unique physiological changes in pediatric patients, ensuring appropriate dosing across different age groups. Their commitment to investigator-initiated studies further underscores their dedication to optimizing treatment outcomes by understanding the benefits and risks associated with their therapies.

United States

AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on identifying, acquiring, developing and commercializing therapies for the unmet medical needs of critical care patients and those with severe, often rare, disorders for which few effective treatments are available.

AltaThera Pharmaceuticals

Company Details